Filing Flows › Health Care › SkinHealth Systems (SKIN)
SkinHealth Systems (SKIN) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · SkinHealth Systems (SKIN) Q3 2026 earnings results →
Q3 2026 Revenue down 2% year over year to $69.2M · 1¢ of every $1 of revenue lost · operating margin 7.2%
SkinHealth Systems made $69.2M in Q3 2026 (-2% Y/Y): Consumables $50.4M, Delivery Systems $18.8M. Operating margin 7.2%, net loss $888K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $69.2M in Q3 2026, down 2% year over year and down 4% from the previous quarter. Consumables was the largest line at 73% of revenue. Delivery Systems lost $2.1M year over year (down 10%), 139% of the total change.
Gross margin was 68.2%, up 3.6 points from Q3 2025. Operating profit was $5.0M, a 7.2% margin (up 16.0 points year over year). Operating expenses fell 19% while revenue fell 2%. The quarter ended with a net loss of $888K, narrower than the previous quarter's $2.7M loss. Net interest and other expense of $5.1M was the main reason.
Operating cash flow was $11.3M (up 17% year over year). Non-cash charges added back $4.0M of depreciation and amortization and $1.4M of share-based compensation. Working capital and other items added $6.7M. Capital expenditures of $93K left free cash flow of $11.2M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 5, 2026 | $69.2M | -2% | 7.2% | −$888K | $11.3M |
| Q2 2026 | 10-Q | Aug 6, 2026 | $72.1M | -8% | 5.0% | −$2.7M | $2.7M |
| Q1 2026 | 10-Q | May 7, 2026 | $64.9M | -7% | -2.8% | −$6.6M | −$5.6M |
| Q4 2025 | 10-K | Mar 12, 2026 | $82.4M | -1% | 0.2% | −$8.1M | $15.2M |
| Q3 2025 | 10-Q | Nov 6, 2025 | $70.7M | -10% | -8.8% | −$11.0M | $9.6M |
| Q2 2025 | 10-Q | Aug 7, 2025 | $78.2M | -14% | -3.5% | $19.7M | $9.6M |
| Q1 2025 | 10-Q | May 8, 2025 | $69.6M | -14% | -17.3% | −$10.1M | $3.0M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About SkinHealth Systems
The Beauty Health Company (the “Company” or “we”) is a global medical aesthetics company delivering an integrated ecosystem of clinically proven solutions designed to help consumers achieve superior skin health and support the success of providers. Anchored by Hydrafacial, a leading and widely requested professional skincare treatment, and supported by complementary offerings including SkinStylus microneedling and HydraScalp powered by Keravive, the Company combines advanced device technology, proprietary consumables, and clinical validation to deliver trusted treatment experiences through an omnichannel network of providers worldwide.
In its own words, from its 10-K, filed Mar 12, 2026.
SkinHealth Systems against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -2% against the peers' median +5%. Operating margin: 7.2% against the peers' median 13.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| SKIN SkinHealth Systems | Q3 2026 | $69.2M | -2% | 7.2% |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: SkinHealth Systems 10-Q on SEC EDGAR · CIK 1818093 · Surgical & Medical Instruments & Apparatus
Guidance and outlook
13F: who owns SKIN and who is buying
More on SKIN
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results